{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:24Z","timestamp":1786119264119,"version":"build-2736575974"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.1097\/bor.0b013e32832efe55","type":"journal-article","created":{"date-parts":[[2009,8,13]],"date-time":"2009-08-13T14:53:58Z","timestamp":1250175238000},"page":"483-488","source":"Crossref","is-referenced-by-count":12,"title":["B cell depletion in lupus and Sj\u00f6gren's syndrome: an update"],"prefix":"10.1097","volume":"21","author":[{"given":"Andreea","family":"Coca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210128","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/jid.2008.240","article-title":"B cells and immunological tolerance","volume":"129","author":"Manjarrez-Orduno","year":"2009","journal-title":"J Invest Dermatol"},{"key":"R3-8-20210128","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1002\/art.24341","article-title":"A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college London hospital: the first fifty patients","volume":"61","author":"Lu","year":"2009","journal-title":"Arthritis Rheum"},{"key":"R4-8-20210128","first-page":"826","article-title":"Long-term clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus","volume":"35","author":"Lindholm","year":"2008","journal-title":"J Rheumatol"},{"key":"R5-8-20210128","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2215\/CJN.04030808","article-title":"Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome","volume":"4","author":"Melander","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"R6-8-20210128","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1093\/ndt\/gfp002","article-title":"Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study","volume":"24","author":"Boletis","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"R7-8-20210128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1177\/0961203307085251","article-title":"Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature","volume":"17","author":"Erre","year":"2008","journal-title":"Lupus"},{"key":"R8-8-20210128","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1136\/ard.2007.078402","article-title":"B cell depletion therapy for patients with systemic lupus erythematosus results in a significant drop in anticardiolipin antibody titres","volume":"67","author":"Ioannou","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R9-8-20210128","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/rheumatology\/ken210","article-title":"Prevalence, serological features, response to treatment and outcome of critical peripheral ischaemia in a cohort of lupus patients","volume":"47","author":"Jeffery","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"R10-8-20210128","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1093\/rheumatology\/ken421","article-title":"Severe acute thrombotic exacerbation in two cases with antiphospholipid syndrome after retreatment with rituximab in phase I\/II clinical trial for refractory systemic lupus erythematosus","volume":"48","author":"Suzuki","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"R11-8-20210128","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/ard.2006.057885","article-title":"Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system","volume":"66","author":"Tokunaga","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R12-8-20210128","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1177\/1352458508098268","article-title":"Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders","volume":"15","author":"Petereit","year":"2009","journal-title":"Mult Scler"},{"issue":"Suppl 3","key":"R13-8-20210128","doi-asserted-by":"crossref","first-page":"iii64","DOI":"10.1136\/ard.2008.097972","article-title":"Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies","volume":"67","author":"Calabrese","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R14-8-20210128","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1002\/art.22657","article-title":"Progressive multifocal leukoencephalopathy in rheumatic diseases: evolving clinical and pathologic patterns of disease","volume":"56","author":"Calabrese","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R15-8-20210128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.clim.2007.11.012","article-title":"A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery","volume":"126","author":"Sutter","year":"2008","journal-title":"Clin Immunol"},{"key":"R16-8-20210128","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2165\/00003495-200666150-00004","article-title":"B-cell-targeted therapy for systemic lupus erythematosus","volume":"66","author":"Sabahi","year":"2006","journal-title":"Drugs"},{"key":"R17-8-20210128","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/01.bor.0000133660.52599.f6","article-title":"B cells in human and murine systemic lupus erythematosus","volume":"16","author":"Anolik","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"R18-8-20210128","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"R19-8-20210128","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/ard.2007.083162","article-title":"Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus","volume":"67","author":"Albert","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R20-8-20210128","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/ard.2007.079418","article-title":"B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response","volume":"67","author":"Cambridge","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R21-8-20210128","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1172\/JCI38010","article-title":"The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus","volume":"119","author":"Cancro","year":"2009","journal-title":"J Clin Invest"},{"key":"R22-8-20210128","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1002\/art.22810","article-title":"Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy","volume":"56","author":"Anolik","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R23-8-20210128","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/adc.2007.126276","article-title":"B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus","volume":"93","author":"Podolskaya","year":"2008","journal-title":"Arch Dis Child"},{"key":"R24-8-20210128","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1542\/peds.2008-2361","article-title":"B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus","volume":"123","author":"Kumar","year":"2009","journal-title":"Pediatrics"},{"key":"R25-8-20210128","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1002\/art.22604","article-title":"Will targeting B cells be the answer for Sjogren's syndrome?","volume":"56","author":"Looney","year":"2007","journal-title":"Arthritis Rheum"},{"key":"R26-8-20210128","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"Dass","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R27-8-20210128","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1136\/ard.2008.092601","article-title":"Treatment of primary Sjogren syndrome with rituximab: extended follow-up, safety and efficacy of retreatment","volume":"68","author":"Meijer","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R28-8-20210128","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1038\/sj.ki.5001777","article-title":"Update on the treatment of lupus nephritis","volume":"70","author":"Waldman","year":"2006","journal-title":"Kidney Int"},{"key":"R29-8-20210128","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1053\/j.ajkd.2003.12.008","article-title":"Treatment of proliferative lupus nephritis","volume":"43","author":"Balow","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R30-8-20210128","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1177\/0961203308095139","article-title":"New therapies in systemic lupus erythematosus - trials, troubles and tribulations.\u2026 working towards a solution","volume":"17","author":"Isenberg","year":"2008","journal-title":"Lupus"},{"key":"R31-8-20210128","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1097\/01.bor.0000240357.22680.63","article-title":"Clinical trial design in systemic lupus erythematosus","volume":"18","author":"Dall'Era","year":"2006","journal-title":"Curr Opin Rheumatol"},{"key":"R32-8-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1177\/0961203308100843","article-title":"New therapies in systemic lupus erythematosus \u2013 trials, troubles and tribulations \u2013 working towards a solution: part 2: the politically incorrect version","volume":"18","author":"Wallace","year":"2009","journal-title":"Lupus"},{"key":"R33-8-20210128","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1136\/ard.2007.083030","article-title":"EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints","volume":"68","author":"Bertsias","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"R34-8-20210128","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jaut.2009.02.006","article-title":"Why can't we find a new treatment for SLE?","volume":"32","author":"Eisenberg","year":"2009","journal-title":"J Autoimmun"},{"key":"R35-8-20210128","doi-asserted-by":"crossref","first-page":"191","DOI":"10.3109\/s10165-007-0565-z","article-title":"A multicenter phase I\/II trial of rituximab for refractory systemic lupus erythematosus","volume":"17","author":"Tanaka","year":"2007","journal-title":"Mod Rheumatol"},{"key":"R36-8-20210128","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.autrev.2008.11.006","article-title":"Use of rituximab in patients with systemic lupus erythematosus: an update","volume":"8","author":"Garcia-Carrasco","year":"2009","journal-title":"Autoimmun Rev"},{"key":"R37-8-20210128","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1136\/ard.2008.091124","article-title":"Prolonged B-cell depletion following rituximab therapy in systemic lupus erythematosus: a report of two cases","volume":"67","author":"Lu","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"R38-8-20210128","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to antitumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"R39-8-20210128","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ctrv.2005.05.007","article-title":"Tolerability and safety of rituximab (MabThera)","volume":"31","author":"Kimby","year":"2005","journal-title":"Cancer Treat Rev"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/BOR.0b013e32832efe55","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:08:07Z","timestamp":1786039687000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002281-200909000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0b013e32832efe55","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}